Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non-small cell lung cancer

Seminars in Oncology

Volumn 28, Issue 3 SUPPL. 9, 2001, Pages 5-9

  Lynch Jr, Thomas J ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Thomas J Lynch   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; IFOSFAMIDE; NAVELBINE; OPIATE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PACLITAXEL; RADIOSENSITIZING AGENT; TAXOID; VINBLASTINE;

ADVANCED CANCER; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEBRILE NEUTROPENIA; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; COMPARATIVE STUDY; LUNG TUMOR; MORTALITY; REVIEW; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; PACLITAXEL; QUALITY OF LIFE; RADIATION-SENSITIZING AGENTS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE; TAXOIDS; VINBLASTINE;

EID: 0034968786     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.24601     Document Type: Article

References (18)

1. A prospective randomized trial of docetaxel (taxotere) versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
2. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with a platinum containing agent
3. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
4. Locally advanced, unresectable non-small cell lung cancer: New treatment strategies
5. Management issues for stage IV non-small cell lung cancer
6. What does chemotherapy have to offer patients with advanced-stage non-small cell lung cancer?
7. Do newer chemotherapeutic agents improve survival in non-small cell lung cancer?
8. Phase II trials of taxotere with non-small cell lung cancer
9. Phase II study of docetaxel for advanced or metastatic platinum refractory non-small cell lung cancer
10. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer
11. Docetaxel (taxotere) in platinum-treated non-small cell lung cancer: A confirmation of prolonged survival in a multicenter trial
12. Phase II study of docetaxel (taxotere) in first- and second-line NSCLC
13. Docetaxel in the management of advanced non-small cell lung cancer
14. Single agents in the second-line treatment of non-small cell lung cancer
15. Survival advantage for patients with stage IV NSCLC treated with single agent navelbine in a randomized controlled trial
16. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: A randomized trial
17. Randomized phase II trial of navelbine (NVB) vs NVB + CDDP (NP) in patients (pts) with inoperable non small cell lung cancer (NSCLC)
18. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a European multicenter trial including 612 patients